Norwegian MDx Firm DiaGenic Raises $12.1M While Refocusing Business on Neuro Market

DiaGenic has developed quantitative real-time PCR-based blood tests for Alzheimer's disease and breast cancer, but will refocus its business primarily on its neuroscience-related molecular tests as opposed to its oncology tests, a company executive said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.